Alnylam Pharmaceuticals, Inc.
HealthcareNASDAQ:ALNY · NASDAQ Global Select
-$5.82 today
Vol 0.83M · Avg 1.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
39.8%
avg 8.6%
ROIC
13.7%
avg -24.7%
ROA
6.3%
avg -23.2%
Analysis
ROE is currently the strongest return metric at 39.8% versus its period average of 8.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Yvonne L. Greenstreet | Chief Executive Officer & Director | $4.99M | — | 63 | $98,364.00 | 0.07% |
Pushkal Garg | Executive VP & Chief Research & Development Officer | $1.86M | — | 58 | $20,443.00 | 0.02% |
Jeffrey V. Poulton | Chief Financial Officer & Executive Vice President | $1.70M | — | 58 | $64,159.00 | 0.05% |
Tolga Tanguler | Executive Vice President & Chief Commercial Officer | $1.50M | — | 53 | $36,500.00 | 0.03% |
Kevin Joseph Fitzgerald | Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development | $1.23M | — | 58 | $20,870.00 | 0.02% |
Bryan Andrew Supran | Chief Legal Officer | $845,920.00 | — | 56 | $14,565.00 | 0.01% |
Phillip A. Sharp | Co-Founder, Member of the Scientific Advisory Board | $52,930.00 | — | 81 | $11,250.00 | <0.01% |
Melissa McLaughlin | Chief Human Resources Officer | — | — | — | $9,443.00 | <0.01% |
Piyush Sharma | Chief Ethics & Compliance Officer | — | — | — | — | — |
Timothy J. Maines | Chief Technical Operations & Quality Officer | — | — | — | — | — |
Christine Regan Akinc | Chief Corporate Communications Officer | — | — | 44 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
147
$20.50M
Net Sentiment
$20.50M
Net selling
Most Active
Garg Pushkal
37 transactions
1–10 of 147
Analysis
Insiders reported 0 buys worth $0.00 and 147 sells worth $20.50M over the last 12 months. That adds up to net selling of $20.50M. Garg Pushkal was the most active insider with 37 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | -14.9% | +45.8% (15yr)10 analysts |
| Net Income | N/A | N/A | N/A | N/A10 analysts |
| EBIT | N/A | N/A | N/A | N/A10 analysts |
Analysis
Recent growth has been strongest in Revenue at -14.9% over three years. Forward estimates point to Revenue at +45.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Cigna Corporation
NYSE:CI
$78.84B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.39B
argenx SE
NASDAQ:ARGX
$55.60B
Cencora, Inc.
NYSE:COR
$54.91B
Becton, Dickinson and Company
NYSE:BDX
$52.79B
Cardinal Health, Inc.
NYSE:CAH
$52.29B
Edwards Lifesciences Corporation
NYSE:EW
$48.81B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.13B
Zoetis Inc.
NYSE:ZTS
$33.65B
Veeva Systems Inc.
NYSE:VEEV
$25.80B
Who manages ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) lists 11 active executives. The top listed executive is Jeffrey V. Poulton, Chief Financial Officer & Executive Vice President.
Are ALNY insiders buying or selling?
Recent insider activity shows net buying of $8.36M.
Explore More
Continue the stock analysis
Jump to another research area for this company.